4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity

Author(s): Fang Liu, Baoding Tang, Hao Liu, Leina Li, Gang Liu, Yun Cheng, Yan Xu, Wenwen Chen, Yinjiu Huang

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 16 , Issue 12 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


4-Anilinoquinazoline derivatives possess high anti-cancer activities. Many of them are highly selective tyrosine kinase inhibitors (TKI), particularly against epidermal growth factor receptor (EGFR). EGFRs are overexpressed or mutated in most carcinomas and are required for tumor progression. The efficacy of EGFR-targeted anti-tumor drugs is impaired by drug-induced acquired resistance. Therefore, there is urgency to find better anti-cancer agents with novel effects on EGFR. 4-Anilinoquinazolines are small molecule EGFR inhibitors that have been synthesized and assessed for their anti-tumor bioactivity. In this paper, we review the 4-anilinoquinazoline derivatives with EGFR inhibitor activity reported in recent years.

Keywords: 4-anilinoquinazoline, Anti-tumor activity, Epidermal growth factor receptor (EGFR).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 03 November, 2016
Page: [1652 - 1664]
Pages: 13
DOI: 10.2174/1871520616666160404113141
Price: $65

Article Metrics

PDF: 36
PRC: 1